Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517593 · ClinicalTrials.gov registry record · Phase 1
Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake
A Phase 1 study of Breast Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 2
- Study locations
NCT02517593: Completed Phase 1 study of Breast Cancer, sponsored by Mayo Clinic.
NCT02517593 is a Phase 1 study of Breast Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 151 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02517593, a Phase 1 study of Breast Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS), in addition to the standard National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer
Conditions Studied
Interventions
- GENETIC Polygenic Risk Score
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
Manitoba
- CancerCare Manitoba - Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 1 |
What the finished NCT02517593 record still lists
NCT02517593 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Polygenic Risk Score is the first listed.
NCT02517593 reports a single indexed study location in Minnesota, Manitoba.
Frequently Asked Questions
What is clinical trial NCT02517593 about?
NCT02517593 is a clinical study titled "Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake". The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS), in addition to the standard National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, will aid women at risk of breast cancer in making a decision to ...
What is the current status of trial NCT02517593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2016-03. Estimated completion is 2019-12-01.
What conditions does trial NCT02517593 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02517593?
The interventions under investigation include: Polygenic Risk Score (GENETIC).
Who is sponsoring clinical trial NCT02517593?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02517593 being conducted?
This trial has 2 study locations across Minnesota, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02517593's enrollment target sits among peer trials
151 443rd of 1224 higher than 782 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia